5734-67-8

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE is used as an intermediate in the synthesis of pharmaceuticals for its potential antitumor and antiviral properties. Its unique structure allows it to be a key component in the development of new drugs targeting various diseases.
Used in Agrochemical Industry:
4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE is used as an intermediate in the synthesis of agrochemicals, specifically as a potential herbicide. Its ability to control or kill unwanted plants makes it a valuable compound in agricultural applications.
Used in Medicinal Chemistry Research:
4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE is utilized in medicinal chemistry for its potential therapeutic applications. Researchers are investigating its properties to develop new treatments for various health conditions, capitalizing on its antitumor and antiviral capabilities.
Used in Agricultural Science Research:
In agricultural science, 4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE is studied for its potential as a herbicide. Its effectiveness in controlling plant growth is of interest to scientists working on innovative and sustainable agricultural solutions.

InChI:InChI=1/C6H8ClN3/c1-2-4-3-5(7)10-6(8)9-4/h3H,2H2,1H3,(H2,8,9,10)

Upstream product

• 5734-66-7 6-ethylisocytosine 
• 30414-53-0 methyl propanoyl acetate 
• 5734-66-7 2-amino-6-ethylpyrimidin-4-ol 

Downstream Products

• 514854-12-7 2,4-diamino-6-ethylpyrimidine 
• 1193-85-7 4-ethylpyrimidin-2-amine 
• 514854-15-0 2-amino-6-ethyl-4-methoxypyrimidine 
• 570415-41-7 N-(2-amino-6-ethyl-4-pyrimidinyl)-N-[4-(4-pyridinylsulfanyl)phenyl]amine 
• 569658-12-4 4-({4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl}sulfanyl)phenol 
• 570415-02-0 6-ethyl-N₄-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]-2,4-pyrimidinediamine 
• 514854-13-8 2,4-diamino-6-ethyl-5-iodopyrimidine 
• 58-14-0 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine 

Relevant academic research and scientific papers

4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H3 Receptor Agonists with in Vivo Central Nervous System Activity

Despite the high diversity of histamine H3 receptor (H3R) antagonist/inverse agonist structures, partial or full H3R agonists have typically been imidazole derivatives. An in-house screening campaign intriguingly afforded

Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H 4 receptor antagonists

This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. Building on our SAR studies of saturated derivatives from the indole carboxamide series, typified by JNJ 7777120, and incorporating knowledge from the tricyclic pyrimidines led us to the 6-alkyl-2,4-diaminopyrimidine series. A focused medicinal chemistry effort delivered several 6-alkyl-2,4-diaminopyrimidines that behaved as antagonists at both the human and rodent H4 receptor. Further optimization led to a panel of antagonists that were profiled in animal models of inflammatory disease. On the basis of the preclinical profile and efficacy in several animal models, JNJ 39758979 was selected as a clinical candidate; however, further development was halted during phase II because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.

CHEMICAL COMPOUNDS

The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Pyrimidine Derivatives As HSP90 Inhibitors

The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR3; R1 is a monocyclic or bicyclic carbocyclic or

Structural studies on bioactive compounds. Part 37. Suzuki coupling of diaminopyrimidines: A new synthesis of the antimalarial drug pyrimethamine

Suzuki reactions have been used successfully to effect cross-coupling of 5-halopyrimidines with 4-chlorobenzeneboronic acid and 2,4-diamino-5-(4-chloro-3-halo)-6-ethylpyrimidines with 4-methoxybenzeneboronic acid. The antimalarial drug pyrimethamine has been prepared by coupling 2,4-diamino-6-ethyl-5-iodopyrimidine with 4-chlorobenzeneboronic acid.